EDX Medical Group PLC Posting of Notice of AGM (1782L)
04 September 2023 - 8:00AM
UK Regulatory
TIDMEDX
RNS Number : 1782L
EDX Medical Group PLC
04 September 2023
Posting of Notice of AGM
EDX Medical Group PLC -- EDX
4 September 2023
EDX Medical Group PLC ("EDX Medical" or the "Company"), which
develops innovative digital diagnostic products and services
supporting personalised treatment solutions for cancer, heart
disease, neurology and infectious diseases, announces that its
annual general meeting ("AGM") will be held in the Roosevelt Room
at Brown's Hotel, 33 Albemarle St, London, W1S 4BP at 2:00 p.m. on
Wednesday, 27 September 2023.
The Notice of AGM and Form of Proxy will be posted today, 4
September 2023, to eligible shareholders. Electronic copies will be
shortly available on the Company's website at:
https://edxmedical.co.uk/documents/.
Due to the acquisition of a subsidiary company during the
reporting period, EDX Medical's annual report and accounts will be
published prior to the AGM and resolutions to receive the annual
report and accounts, and to re-appoint the auditors, will be
presented at a later general meeting in October 2023.
Contacts:
EDX Medical PLC
Dr Mike Hudson (Chief Executive Officer) +44 (0)7812 345 301
mike@edxmedical.co.uk
Oberon Capital
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith (Executive Director) +44 (0)7788 414856
Gary McQueen (Associate Director) ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
Notes for Editors:
About EDX Medical Group
www.edxmedical.co.uk
EDX Medical Group PLC develops innovative digital diagnostic
products and services, enabling cost effective and timely delivery
of personalised treatment for cancer, heart disease, neurology and
infectious diseases. The company is listed on the Access Segment of
the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE,
a medical and life sciences entrepreneur with more than 30 years of
experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical operates a molecular biology and diagnostics
laboratory in Cambridge, UK, and the 100%-owned subsidiary "Torax
Biosciences Ltd" (www.toraxbiosciences.co.uk) with a satellite
operation in Ireland. EDX Medical provides testing and genomic
sequencing services, undertakes quality assurance, conducts
research & development (R&D) and has established expertise
in the design, development, validation and sourcing of diagnostic
testing solutions to ISO 13485. Key laboratory tests performed by
the Company have been accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXUAUVROUUKRAR
(END) Dow Jones Newswires
September 04, 2023 02:00 ET (06:00 GMT)
EDX Medical (AQSE:EDX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
EDX Medical (AQSE:EDX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024